Today we celebrate the 81st anniversary of the first radioiodine therapy administered by Dr. Saul Hertz to a patient, thus, marking it the first experience in using the radiotheranostics technique. 8 decades later, his legacy continues, as we are witnessing the rising role of nuclear medicine and radiotheranostics in the cancer setting.
More recently, in March 2022, a great step towards enhancing access to radioligand treatments was achieved when the first PSMA radiotheranostics was approved by the FDA: Lu-177 PSMA-617 for treatment and Ga-68-PSMA kit for PET imaging. Thus, building hope for men living with prostate cancer.
But why do we celebrate World Theranostics Day? First, to recognize the latest therapy and diagnosis highlights. But also, as there is still a lot to be done to raise awareness about the availability and potential of the technology.
From challenges to opportunities, from awareness to readiness, discover what the voices of Oncidium have to say about bringing forward Radiotheranostics Today.